文献速递类风湿关节炎

类风湿关节炎患者一线抗TNF治疗失败后应选用哪种进阶治疗:魁北克RHUMADATA注册研究15年证据

Which advanced treatment should be used following the failure of a first-line anti-TNF in patients with rheumatoid arthritis? 15 years of evidence from the Quebec registry RHUMADATA.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

基于RHUMADATA注册研究2007年1月至2022年11月的数据,纳入611例一线TNFi失败后换药的类风湿关节炎患者,其中320例换用TNFi、291例换用其他作用机制药物(OMA)。多变量分析显示OMA组停药率显著低于TNFi组(adjHR 0.65,95%CI 0.44-0.94),分层分析中利妥昔单抗保留率优于TNFi(adjHR 0.39,95%CI 0.18-0.84)。作者认为换用OMA尤其是利妥昔单抗可能是最佳二线策略。

要点

  • 一线TNFi失败后换用OMA的患者中位保留时间4.48年,换用TNFi者为2.84年。
  • 多变量分析中OMA组停药率显著低于TNFi组,adjHR 0.65(95%CI 0.44-0.94)。
  • 分层分析中利妥昔单抗保留率优于TNFi,adjHR 0.39(95%CI 0.18-0.84)。

核心结论

  • 一线TNFi治疗失败的类风湿关节炎患者换用OMA尤其是利妥昔单抗,似乎是最佳的二线治疗策略。

研究设计与样本

  • 数据提取自RHUMADATA注册研究,自2007年1月起纳入患者,随访至治疗终止、失访或2022年11月25日。
  • 共纳入611例患者,其中320例换用TNFi、291例换用其他作用机制药物(OMA)。
  • 采用Kaplan-Meier法和Cox回归模型比较组间停药情况,并对缺失数据进行插补、计算倾向评分以减少潜在归因偏倚。

主要发现

  • TNFi组和OMA组诊断时平均年龄分别为44.5岁和43.9岁。
  • TNFi组和OMA组的中位保留时间分别为2.84年和4.48年。
  • 多变量分析中OMA组停药率显著低于TNFi组(adjHR 0.65;95%CI 0.44-0.94),倾向评分调整后的多重插补Cox模型结果一致。
  • 分层分析中,调整患者特征后利妥昔单抗保留率优于TNFi(adjHR 0.39;95%CI 0.18-0.84)。

临床怎么用

  • 作者认为,一线TNFi治疗失败后换用OMA尤其是利妥昔单抗似乎是最佳的二线治疗策略(原文未据此给出推荐等级)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since 2000, advanced therapies (AT) have revolutionized the treatment of moderate to severe RA. Randomized control trials as well as observational studies together with medication availability often determine second-line choices after the failure of first TNF inhibitors (TNFi). This led to the observation that specific sequences provide better long-term effectiveness. We investigated which alternative medication offers the best long-term sustainability following the first TNFi failure in RA. METHODS: Data were extracted from RHUMADATA from January2007. Patients were followed until treatment discontinuation, loss to follow-up or 25 November 2022. Kaplan-Meier and Cox regression models were used to compare discontinuation between groups. Missing data were imputed, and propensity scores were computed to reduce potential attribution bias. Complete, unadjusted and propensity score-adjusted imputed data analyses were produced. RESULTS: Six hundred eleven patients [320 treated with a TNFi and 291 treated with molecules having another mechanism of action (OMA)] were included. The mean age at diagnosis was 44.5 and 43.9 years, respectively. The median retention was 2.84 and 4.48 years for TNFi and OMAs groups. Using multivariable analysis, the discontinuation rate of the OMA group was significantly lower than TNFi (adjHR: 0.65; 95% CI: 0.44-0.94). This remained true for the PS-adjusted MI Cox models. In a stratified analysis, rituximab (adjHR: 0.39; 95% CI: 0.18-0.84) had better retention than TNFi after adjusting for patient characteristics. CONCLUSION: Switching to an OMA, especially rituximab, in patients with failure to a first TNFi appears to be the best strategy as a second line of therapy.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Choquette D, Haraoui B, Movahedi M, et al. Which advanced treatment should be used following the failure of a first-line anti-TNF in patients with rheumatoid arthritis? 15 years of evidence from the Quebec registry RHUMADATA. Rheumatology (Oxford). 2025. PMID: 38830031. doi:10.1093/rheumatology/keae283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。